Orion published Half-Year Financial Report 1-6/2022 on Friday, 15 July 2022. The report, related presentation material and a link to a live webcast are available here.
|9/20/2022||Change in Orion Group Executive Management Board as of 1 November 2022 – Juhani Kankaanpää appointed as Senior Vice President of Global Operations|
|9/19/2022||Orion Corporation: Acquisition of Own Shares 19.09.2022|
|9/19/2022||165,797 Orion Corporation A shares converted into B shares|
|9/16/2022||ORION CORPORATION: ACQUISITION OF OWN SHARES 16.09.2022|
The Annual General Meeting of Orion Corporation was held on Wednesday 23 March 2022. The decisions and related material are available here.
Orion’s virtual Capital Markets Day 2021 was held on 26 May 2021. Presentations and webcast from the event are available here.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
|9/5/2022||Orion recalls Devisol Salmiakki dietary supplement from consumers|
|8/8/2022||U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)|
|6/28/2022||Orion publishes Half-Year Financial Report for January–June 2022 on Friday 15 July 2022|
|5/9/2022||The negotiations under the Act on Co-operation within Undertakings concerning Orion’s R&D have been completed – future focus on pain and oncology|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.